ISRCTN73606171已完成未知
Assessing dengue transmission risk and a vector control intervention using entomological and immunological indices in northeastern Thailand: a cluster-randomized controlled trial
orwegian University of Life Sciences0 个研究点目标入组 539 人开始时间: 2017年6月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 539
研究概览
简要总结
2018 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/29458406 protocol 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34043621/ (added 11/07/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Within ring roads of each strata (city), populated residential areas.
- •All points of the cluster are at least 100 m from the nearest point of the village border.
- •1. Households that are permanently inhabited
- •2. Households that are built or re-populated during the study period
- •Individuals:
- •1. In households where household head has signed informed consent for household to participate in project
- •2. A travel history outside the village during the previous 7 days
- •3. Chronic diseases such as HIV/AIDS or cancer
- •4. Apparent inability to give informed consent, e.g., due to mental disability or other incapacity, or lack of a legally authorized representative
- •5. Disease with similar symptoms to dengue but with evident alternative explanation
- •6. Age >1 year old
排除标准
- •1. Area <0.125 km2
- •2. Number of houses<100
- •3. Population <300
- •4. Coverage of residential area 70-80% (scattered housing)
- •5. Non-residential areas, e.g. agricultural fields, airport, industrial areas, commercial areas, (e.g. shopping malls), government offices, lakes. army camps, hospitals and schools.
- •1. Apartment buildings
- •2. Abandoned houses
- •3. Non-permanent households
- •1. Refusal to participate in the study
- •2. Age <1 year old
研究者
相似试验
已完成
1 期
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus VaccineDengueNCT01436422National Institute of Allergy and Infectious Diseases (NIAID)112
已完成
1 期
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus VaccineDengueNCT01072786National Institute of Allergy and Infectious Diseases (NIAID)141
已完成
1 期
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus VaccineDengueNCT01506570National Institute of Allergy and Infectious Diseases (NIAID)58
已完成
1 期
Safety and Immune Response to an Investigational Dengue Type 2 VaccineDengue VirusNCT01073306National Institute of Allergy and Infectious Diseases (NIAID)18
已完成
1 期
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 VaccineDengue VirusNCT01084291National Institute of Allergy and Infectious Diseases (NIAID)18
